Thrombopoietin levels in patients with disorders of platelet production: Diagnostic potential and utility in predicting response to TPO Receptor agonists
Authors:
Open Access
- 1 August 2013
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 88 (12) , 1041-1044
Abstract
Thrombopoietin (TPO) is the major regulator of megakaryopoiesis. Measurement of serum TPO levels may help distinguish between various causes of thrombocytopenia and predict treatment response to TPO receptor agonists. Serum TPO levels from 118 healthy volunteers and 88 patients with abnormal platelet counts were measured using a quantitative ELISA assay. The mean (range) TPO level in healthy volunteers was 39 (7–99) pg/mL. TPO values were correlated with the patient's diagnosis, platelet count, and response to TPO receptor agonists. 88 patients with history of consumptive thrombocytopenia (39) or hypoproliferative thrombocytopenia (49) were analyzed. Median (interquartile range) TPO level for consumptive thrombocytopenia patients was 63 (48–98) pg/mL with a corresponding median (interquartile range) platelet count of 73 (28–146) × 109/L. In contrast, hypoproliferative thrombocytopenia patients had platelet counts [59 (30–117) × 109/L] comparable with consumptive thrombocytopenia patients, but significantly higher serum TPO levels [706 (358–1546) pg/mL, P < 0.0001]. Analysis of 21 ITP patients treated with TPO receptor agonists demonstrated that a TPO level >95 pg/mL was associated with lack of clinical response (P < 0.002). TPO levels may have diagnostic utility in discriminating between patients with hypoproliferative and consumptive thrombocytopenia. Elevated TPO levels in ITP patients may predict a poor clinical response to treatment with TPO receptor agonists. Am. J. Heamtol. 88:1041–1044, 2013.Keywords
This publication has 25 references indexed in Scilit:
- Thrombopoietin and Platelet Production in Chronic Immune ThrombocytopeniaHematology/Oncology Clinics of North America, 2009
- Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet productionBritish Journal of Haematology, 2009
- Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working groupBlood, 2009
- Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic PurpuraNew England Journal of Medicine, 2007
- Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnoverBone Marrow Transplantation, 2006
- Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodiesAmerican Journal of Hematology, 2004
- Plasma thrombopoietin levels in thrombocytopenic states: implication for a regulatory role of bone marrow megakaryocytesBritish Journal of Haematology, 1998
- Megakaryocyte growth and development factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia.Journal of Clinical Investigation, 1995
- c-Mpl ligand is a humoral regulator of megakaryocytopoiesisNature, 1994
- Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance.Journal of Clinical Investigation, 1987